Insider Selling: Pulmonx Co. (NASDAQ:LUNG) Insider Sells 1,184 Shares of Stock

Pulmonx Co. (NASDAQ:LUNGGet Free Report) insider Geoffrey Beran Rose sold 1,184 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $8.71, for a total transaction of $10,312.64. Following the transaction, the insider now directly owns 305,500 shares of the company’s stock, valued at approximately $2,660,905. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Geoffrey Beran Rose also recently made the following trade(s):

  • On Monday, April 22nd, Geoffrey Beran Rose sold 1,184 shares of Pulmonx stock. The shares were sold at an average price of $7.49, for a total transaction of $8,868.16.
  • On Friday, March 22nd, Geoffrey Beran Rose sold 1,184 shares of Pulmonx stock. The shares were sold at an average price of $9.36, for a total transaction of $11,082.24.
  • On Friday, March 1st, Geoffrey Beran Rose sold 3,097 shares of Pulmonx stock. The shares were sold at an average price of $9.06, for a total transaction of $28,058.82.

Pulmonx Trading Down 6.4 %

Shares of Pulmonx stock traded down $0.57 on Thursday, hitting $8.38. 158,994 shares of the company’s stock were exchanged, compared to its average volume of 492,217. The company has a 50-day simple moving average of $8.51 and a 200-day simple moving average of $10.74. Pulmonx Co. has a 1 year low of $7.11 and a 1 year high of $14.84. The company has a current ratio of 6.95, a quick ratio of 6.14 and a debt-to-equity ratio of 0.29.

Pulmonx (NASDAQ:LUNGGet Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. The business had revenue of $18.85 million for the quarter, compared to analysts’ expectations of $17.54 million. Pulmonx had a negative net margin of 80.46% and a negative return on equity of 48.09%. During the same quarter last year, the company posted ($0.42) EPS. As a group, research analysts forecast that Pulmonx Co. will post -1.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on LUNG. Stifel Nicolaus raised their target price on shares of Pulmonx from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. Wells Fargo & Company reissued an “equal weight” rating and set a $14.00 price target (down previously from $16.00) on shares of Pulmonx in a research report on Friday, February 23rd. Canaccord Genuity Group reduced their price target on shares of Pulmonx from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. Piper Sandler reissued an “overweight” rating and set a $17.00 price target on shares of Pulmonx in a research report on Wednesday, April 3rd. Finally, Citigroup raised their price target on shares of Pulmonx from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.33.

Get Our Latest Report on LUNG

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its holdings in Pulmonx by 4.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 35,720 shares of the company’s stock worth $332,000 after buying an additional 1,633 shares during the period. Sei Investments Co. boosted its holdings in Pulmonx by 2.5% in the 1st quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock worth $673,000 after buying an additional 1,800 shares during the period. Bank of New York Mellon Corp boosted its holdings in Pulmonx by 2.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 159,712 shares of the company’s stock worth $1,650,000 after buying an additional 3,900 shares during the period. New York State Common Retirement Fund boosted its holdings in Pulmonx by 32.7% in the 4th quarter. New York State Common Retirement Fund now owns 17,495 shares of the company’s stock worth $223,000 after buying an additional 4,311 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Pulmonx by 609.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock worth $79,000 after buying an additional 7,316 shares during the period. Institutional investors own 91.04% of the company’s stock.

Pulmonx Company Profile

(Get Free Report)

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

Featured Articles

Insider Buying and Selling by Quarter for Pulmonx (NASDAQ:LUNG)

Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.